Fig. 1: The association of SNORD50A/B deletion with patient survival in breast cancers with different p53 settings. | Cell Death & Differentiation

Fig. 1: The association of SNORD50A/B deletion with patient survival in breast cancers with different p53 settings.

From: The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53

Fig. 1

a SNORD50A/B deletion frequency in 6 types of human cancers. b The association of SNORD50A/B deletion with poor patient survival in breast cancers (number of deletion group:188; number of wild-type group: 309), hepatocellular carcinomas (number of deletion group:28; number of wild-type group: 106) and lung adenocarcinomas (number of deletion group:21; number of wild-type group: 91). c The relationship between SNORD50A/B deletion and patient survival in breast cancers with mutant p53 (number of deletion group:41; number of wild-type group: 129) or wild-type p53 (number of deletion group:147; number of wild-type group: 180). d The relationship between p53 mutations and patient survival in breast cancers with deleted SNORD50A/B (number of mutation group:41; number of wild-type group: 147) or wild-type SNORD50A/B (number of mutation group:129; number of wild-type group: 180). All the data were from TCGA database.

Back to article page